跳至主要内容
临床试验/NCT03483922
NCT03483922已完成不适用

Clinical Trials on Detection of Hepatocellular Carcinoma With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC and T Cells

HKGepitherapeutics1 个研究点 分布在 1 个国家目标入组 403 人开始时间: 2018年8月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
403
试验地点
1
主要终点
Calculation of M Scores and HCC Probability Scores

研究概览

简要总结

Hepatocellular Carcinoma (HCC) is the fifth most common cancer world-wide. It is particularly prevalent in Asia, and its occurrence is highest in areas where hepatitis B is prevalent, indicating a possible causal relationship. Follow up of high-risk populations such as chronic hepatitis patients and early diagnosis of transitions from chronic hepatitis to HCC would improve cure rates. In most cases HCC is detected late resulting in increased mortality and morbidity.

The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in hepatocellular carcinomas patients.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed diagnosis of HCC by EASL-EORTC guidelines
  • Confirmed hepatitis B diagnosis for HepB patients using AASLD practice guidelines.
  • Exclusion Criteria for HCC:
  • Cirrhosis, any other known inflammatory disease (bacterial or viral infection with the exception of hepatitis B or C, diabetes, asthma, autoimmune disease, active thyroid disease) which could alter T cells and monocytes characteristics
  • Other cancers.
  • Exclusion Criteria for HepB:
  • Diagnosis of HCC or any other cancer.
  • Exclusion Criteria for Healthy Controls:
  • Any known inflammatory or infectious disease including HepB and HepC
  • Chronic diseases,
  • Medications or drug use

排除标准

  • 未提供

结局指标

主要结局

Calculation of M Scores and HCC Probability Scores

时间窗: 6 months to 1 year

We normalized median methylation values (range 0-100) for 'HCC-detect' (Hepatocellular Carcinoma Detection) and 'HCC-spec' (Hepatocellular Carcinoma Specificity). 'HCC-detect' is derived from CHFR, VASH2, CCNJ, and GRID2IP regions, aiming to broadly identify HCC. Theoretical range is -6.6438 to 8.6438, with observed -3.541 to 7.65; higher scores indicate increased HCC likelihood. 'HCC-spec', focusing on the F12 region, differentiates HCC from 31 other cancers and normal cells, with theoretical range -3.3219 to 6.64385 (observed -3.3219 to 6.6297). Higher scores signify greater HCC specificity. Both scores, modeled via logistic regression in Prism, predict HCC probability, linking higher scores with higher HCC likelihood or specificity

次要结局

未报告次要终点

研究者

发起方
HKGepitherapeutics
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验